Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic (2)
STOCKHOLM, May 22, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...
Source: europapress.es
Page 21 - Access Pathway News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Access Pathway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Access Pathway Today - Breaking & Trending Today
Achilles Therapeutics Reports First Quarter 2023 Financial
- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of...
Source: globenewswire.com
CRISPR Therapeutics : Initiated clinical trials for next generation CAR T candidates, CTX112™ targeting CD19+ B-cell malignancies and CTX131™, targeting CD70+ solid tumors - Form 8-K
-Initiated clinical trials for next generation CAR T candidates, CTX112™ targeting CD19+ B-cell malignancies and CTX131™, targeting CD70+ solid tumors- -Enrollment... | May 8, 2023
Source: marketscreener.com
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
-Regulatory submissions complete for exagamglogene autotemcel , formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia and severe sickle cell disease - -EU and U.K.... | May 8, 2023
Source: marketscreener.com
Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit IND
Source: finanznachrichten.de